<DOC>
	<DOCNO>NCT02161991</DOCNO>
	<brief_summary>Aprepitant oral neurokinin-1 ( NK-1 ) antagonist widely use prevention chemotherapy-induced nausea vomiting ( CINV ) , metabolize CYP34A , however , still unknown CINV control rate aprepitant Chinese non-small cell lung cancer ( NSCLC ) patient , hypothesis CYP3A4 NK-1 polymorphism would influence aprepitant plasma concentration , may lead individual difference CINV control rate .</brief_summary>
	<brief_title>Aprepitant Chemotherapy Induced Nausea Vomiting Chinese Advanced Non-small Cell Lung Cancers</brief_title>
	<detailed_description>Patients pathologic diagnose advanced non-small cell lung cancer , accord NCCN non-small cell lung cancer guide line ( 2014 V2 ) , patient receive standard platinum base chemotherapy , randomize divide two group , aprepitant group placebo group . In aprepitant group , patient would receive aprepitant 125 mg day1 , 80 mg day2 day3 . In placebo group , patient would receive placebo day1 day3 . In group , dexamethasone 5-HT inhibitor palonosetron give dose . During treatment , grade nausea vomit record order evaluate complete response rate CINV , side-effects record . In aprepitant group , plasma take analyze plasma concentration , gene polymorphism CYP3A4 NK-1 analyze patient receive aprepitant possible .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>patient pathologic diagnose advanced nonsmall cell lung cancer accord NCCN nonsmall cell lung cancer guide line ( 2014 V2 ) , patient suitable platinum base chemotherapy . patient could receive platinum base chemotherapy judge clinical doctor pregnancy breastfeed woman serious disease could control urine protein≥++ , 24h urine protein＞1g le 18 year old 75 year old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>aprepitant</keyword>
	<keyword>non-small cell lung cancer</keyword>
</DOC>